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Pathogens use variousmechanisms tomanipulate host processes to promote infection. Decades of research
on pathogens have revealed not only the molecular mechanisms that these microbes use to replicate and
survive within host cells, but also seminal information on how host signaling machinery regulates cellular
processes. Among these discoveries are mechanisms involving posttranslational modifications that alter
the activity, localization, or interactions of the modified protein. Herein, we examine how pathogens have
contributed to our basic understanding of three posttranslational modifications: phosphorylation,
NMPylation, and ubiquitylation. Over the years, technologies, techniques and research tools have developed
side by side with the study of pathogens, facilitating the discovery of protein modifications and furthering our
understanding of how they contribute to both infection and cellular functions.Introduction
Pathogens such as bacteria, viruses, fungi, and nematodes use
variousmechanisms to alter cellular processes during their com-
plex interactions with the host. Many of these interactions are
mediated by proteins that are produced by the pathogen and
act inside host cells to manipulate cellular processes and pro-
mote infection. These virulence proteins utilize different mecha-
nisms to regulate host proteins, one of which is posttranslational
modifications (PTMs).
As the host uses PTMs to regulate cellular processes, viru-
lence proteins also use PTMs to manipulate and regulate host
proteins. Some virulence proteins are enzymes that can directly
mediate a PTM of a target, whereas others mediate the PTM of a
host protein in an indirect manner, by recruiting host compo-
nents. The virulence enzymes that directly mediate PTMs can
do so by imitating enzymatic activities that are used by the
host or by using a unique activity. Interestingly, some virulence
enzymes are proposed to have been ‘‘taken’’ from a host and
incorporated into the pathogen’s virulence mechanisms,
whereas others are thought to have risen from convergent
evolution to perform similar activities to those of host enzymes.
Notably, virulence proteins can also take advantage of the host
PTM machinery for their own modification, and thus achieve
additional regulation of their activities, localization, or stability.
One of the first virulence enzymes reported to catalyze a direct
PTM of a host protein was diphtheria toxin, produced by the
pathogenic bacterium Corynebacterium diphtheriae. In the late
1960s, several groups described the mechanism by which
diphtheria toxin blocks host-protein translation and thus leads
to cell death. Two groups independently elucidated that the toxin
hydrolyzes nicotinamide adenine dinucleotide and then transfers
the resulting ADP-ribose to aminoacyl transferase II (elongation
factor-2), resulting in its inactivation and thus a disruption in
protein synthesis (Gill et al., 1969; Honjo et al., 1968). Since
this discovery, many virulence proteins that mediate PTMs and
have a plethora of activities have been described. The target
proteins can be modified by small molecules (e.g., phosphoryla-
tion, acetylation, and AMPylation) or small proteins (e.g., ubiqui-Cetin, SUMO, and NEDD8) as substrates in a reversible manner
(e.g., phosphorylation and AMPylation) or an irreversible manner
(e.g., deamidases, phosphothreonine lyases, and proteases)
(Ribet and Cossart, 2010).
Here, we present a historical discussion of how the study of
host-pathogen interactions led to discoveries of PTM mecha-
nisms. We focus our discussion on three pivotal mechanisms,
phosphorylation, NMPylation, and ubiquitylation, while providing
insights into the biochemical mechanisms and the use of devel-
oping technologies for the discovery of new PTMs.
Phosphorylation
Phosphorylation, the transfer of a g-phosphate of ATP to a
serine, threonine, or tyrosine residue of a protein (and also
histidine and lysine), is a PTM used by all living organisms.
Phosphorylation is a reversible modification, mediated by
enzymes named kinases, that regulates protein activities and
plays pivotal roles in pathogen infections (Ubersax and Ferrell,
2007). Kinases use the readily available ATP as a substrate
and require the presence of a metal ion such as Mg2+ or Mn2+.
Phosphorylation is often used in host-immunity-related signal
transduction cascades, such as mitogen activated protein
kinase (MAPK) pathways, and is thus a lucrative target for
manipulation by pathogens.
In 1954, Burnett and Kennedy provided direct evidence for the
enzymatic phosphorylation of a protein when they described an
enzyme from liver mitochondria that catalyzes the phosphoryla-
tion of casein, an artificial substrate, on a serine residue (Burnett
and Kennedy, 1954). From this initial discovery until 1979, pro-
tein kinases were thought to phosphorylate proteins only on
serine and threonine residues. However, the discovery of the
Src kinase changed that perception.
The Discovery of v-Src
In 1911, Peyton Rous showed that tumors (sarcomas) could be
transmittable using liquid produced from other sarcomas
(Rous, 1911). It was later shown that the causative agent in the
liquid was Rous sarcoma virus (RSV). RSV was one of many
viruses that were found to cause tumors in susceptible cells. Inll Host & Microbe 14, September 11, 2013 ª2013 Elsevier Inc. 269
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describe viral genes that have the potential to cause cancer,
and in the 1970s the RSV oncogene v-Src was found (Huebner
and Todaro, 1969; Martin, 2001). The v-Src protein was isolated
in 1977 by Brugge and Erikson (1977). It was identified as a
protein kinase a year later when the antibody heavy chain, as
well as v-Src itself, was phosphorylated in immunoprecipitates
incubated in kinase buffer with g-32P-labeled ATP (Collett and
Erikson, 1978). This protocol, which became known as the
immune complex kinase assay, became widely used for the
study of protein kinases.
Notably, in 1976, a ‘‘normal’’ cellular gene homologous to
v-Src was discovered in avian genomes (Stehelin et al.,
1976). This gene, named c-src, was termed a ‘‘proto-onco-
gene,’’ a cellular precursor of the viral oncogene. c-Src was
also reported to have kinase activity, although lower than that
of v-Src (Oppermann et al., 1979). Later studies revealed that
Src is a member of a large family of nonreceptor tyrosine
kinases that are found in essentially all metazoan cells (Thomas
and Brugge, 1997). c-Src is a modular protein containing SH2
and SH3 domains, which became prototypes of domains that
mediate protein-protein interactions (Martin, 2001). The study
of the Src modular domains also provided seminal lessons on
protein autoinhibition (Boggon and Eck, 2004; Martin, 2001).
Importantly, the discoveries of proto-oncogenes led to the
realization that mutated versions of these genes can result in
cancer.
Initially, Src was believed to phosphorylate substrates on
threonine residues. However, work by Tony Hunter and col-
leagues on v-Src and the polyomavirus middle T antigen (also
an oncogene) revealed a new mechanism of protein regulation:
tyrosine phosphorylation (Eckhart et al., 1979; Hunter and
Sefton, 1980). They discovered that the highly acidic buffer
used to run hydrolyzed amino protein samples on thin-layer
plates for the detection of phosphorylated residues caused
phosphothreonine and phosphotyrosine to comigrate. Seren-
dipitously, Hunter used an old buffer with a slightly higher
pH, which caused phosphothreonine and phosphotyrosine
to run separately and allowed him to identify tyrosine as
the residue phosphorylated by Src (Hunter, 2008). Thus, tyro-
sine phosphorylation, found later to be catalyzed by many
cellular kinases, emerged as a central mechanism in cellular
regulation.
Subsequent studies aimed at identifying Src phosphorylation
substrates were successful using what were then ground-
breaking techniques and tools. For example, the multifunction
cellular protein p36 (also known as calpactin I or annexin II)
was identified as a substrate of v-Src in 1979 with the use of
high-resolution two-dimensional gel electrophoresis (Erikson
and Erikson, 1980; Radke and Martin, 1979), a technique devel-
oped in 1975 that allowed for distinct separation of modified
cellular proteins (O’Farrell, 1975). This technique was later
improved byCooper andHunter for detection of Src phosphotyr-
osine-containing substrates, exploiting the alkali stability of
phosphotyrosine to reduce background signals (Cooper and
Hunter, 1981). Another important tool used in the hunt for Src
substrates, as well as for other kinases, came with the develop-
ment of antibodies that recognized phosphorylated tyrosine res-
idues (Frackelton et al., 1983).270 Cell Host & Microbe 14, September 11, 2013 ª2013 Elsevier IncRegulation of Protein Activities by Kinases and
Phosphatases
After the discovery of tyrosine phosphorylation by Hunter and
colleagues, many tyrosine kinases were identified in eukaryotes,
and tyrosine phosphorylation was found to have an important
role in various cellular processes, such as growth factor
signaling and proliferation, cancer (as discussed above for viral
oncogenes and cellular proto-oncogenes), and activation of
MAPK pathways (Gschwind et al., 2004; Lemmon and Schles-
singer, 2010). The importance of tyrosine phosphorylation for
pathogenesis and immune responses was underscored by the
discovery of a bacterial protein tyrosine phosphatase (PTP). In
1990, Guan and Dixon identified a bacterial PTP using database
mining (Guan and Dixon, 1990). The gene encoded the Yersinia
type III effector YopH, which was known to be required for the
virulence of this bacterium (Bo¨lin and Wolf-Watz, 1988). Inter-
estingly, by aligning the catalytic residues of YopH with other
known eukaryotic PTPs, the authors raised the possibility that
YopH had a eukaryotic origin that was reminiscent of the
eukaryotic origins for the viral tyrosine kinase v-Src (Guan and
Dixon, 1990). It is worth noting that at the time YopH was
discovered, tyrosine phosphorylation was not considered a
nonmetazoan signaling mechanism; however, the subsequent
discovery of PTPs in various microorganisms refuted that para-
digm (Heneberg, 2012). YopH is one of the most potent PTPs
isolated to date and plays an essential role in virulence by tar-
geting various signaling pathways required for host immunity
(Bliska et al., 1991). Several phosphorylated tyrosine kinases
and adaptors have been detected as YopH substrates (de la
Puerta et al., 2009; Hamid et al., 1999; Persson et al., 1997).
Notably, YopH was shown to inhibit the uptake of Yersinia by
host cells by disrupting peripheral focal adhesion complexes,
which contribute to cellular structure and spreading (Persson
et al., 1997), and suppressing T and B lymphocyte activation
(Yao et al., 1999).
A year after the report of the PTP YopH, Dixon and colleagues
discovered another PTP-like protein in vaccinia virus, named
VH1 (Guan et al., 1991). VH1 shares amino acid sequence iden-
tity with catalytic residues of PTPs, which are structurally
and catalytically distinct from serine/threonine phosphatases
(Barford, 1995). Surprisingly, however, VH1 was able to hydro-
lyze both substrates containing phosphotyrosine and substrates
containing phosphoserine, identifying this viral protein as a dual
specificity phosphatase (DSP) (Guan et al., 1991). VH1, which is
highly conserved among poxviruses and is essential for vaccinia
viability in tissue culture (Liu et al., 1995), dephosphorylates the
transcription factor STAT1 to downregulate the cellular antiviral
response (Najarro et al., 2001).
Soon after the discovery of the DSP VH1, reports on eukary-
otic PTPs began to appear (Guan et al., 1992). VH1 is now
considered the prototype of a family of VH1-like DSPs, a sub-
class of PTPs. Members of this family are found in viruses, yeast,
plants, and higher eukaryotes, where they control many cellular
aspects such as MAPK activation, immune responses, and
embryogenesis (Camps et al., 2000; Fauman and Saper, 1996;
Pulido and Hooft van Huijsduijnen, 2008).
In 1993, a direct role for serine/threonine phosphorylation was
found in bacterial pathogenesis. Examination of amino acid
sequences identified Yersinia YpkA (YopO), an effector delivered.
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Figure 1. Pathogens Antagonize Host
Signaling
(A) Yersinia YopJ acetylates serine/threonine
residues on the activation loop of MAPKKs
(‘‘MKK’’) to prevent activation by phosphorylation.
(B) Shigella OspF uses b-eliminylation to remove
the phosphate from a phosphorylated MAPK,
resulting in an irreversibly inactive kinase.
(C) Xhanthomonas campestris AvrAC uses
UMPylation to modify MAPK kinases on serine/
threonine residues within the activation loop of
MAPKKs to prevent phosphorylation-mediated
activation.
(D) The family of Cif-like effectors deamidate
ubiquitin, resulting in substrates that cannot be
used for ubiquitin elongation.
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secreted bacterial protein kinase involved in pathogenicity
(Galyov et al., 1993). Similar to other bacterial toxins, YpkA is a
modular protein. Aside from its kinase domain, it also contains
a domain that mimics host guanidine nucleotide dissociation
inhibitors (GDIs), which prevent guanosine triphosphate (GTP)
exchange of small GTPases (Prehna et al., 2006). Remarkably,
YpkA kinase activity is positively regulated by binding to host
monomeric (G) actin (Juris et al., 2000). This form of positive
regulation by binding a host cofactor prevents promiscuous
activity of the effector before its translocation into the host.
The kinase activity of YpkA is used to phosphorylate a serine
residue on the conserved diphosphate binding loop of the active
GTP-bound form of Gaq, involved in many cell pathways, which
decreases its affinity for GTP and thereby inhibits Gaq signaling
pathways in host cells (Navarro et al., 2007).
Following the discovery of YpkA, additional virulence determi-
nants that are eukaryotic-like serine/threonine protein kinases
have been described as substrates of various bacterial protein
secretion systems (Hervet et al., 2011; Walburger et al., 2004).
An interesting example is the Shigella type III effector, OspG,
which was identified in 2005 as a kinase that exhibits similarities
to eukaryotic serine/threonine kinases (Kim et al., 2005). How-
ever, OspG and its homologs NleH1 and NleH2, found in Escher-
ichia coli, are atypical kinases that lack subdomains VIII–XI out of
the eleven subdomains found in typical serine/threonine kinases
(Zhou et al., 2013). Therefore, OspG lacks the activation loop
found in subdomain VIII, which usually stimulates kinase activity
upon phosphorylation. Nevertheless, OspG was recently found
to use an activation mechanism similar to that of YpkA. Instead
of binding monomeric (G) actin, OspG binds host ubiquitin to
stimulate its kinase activity (Zhou et al., 2013). Although the
search for a target of OspG phosphorylation is ongoing, the
kinase activity of OspG is required to prevent the phospho-
IkBa degradation and NF-kB activation that are induced upon
stimulation with the inflammatory cytokine TNF-a, thus damp-
ening host innate immune responses (Kim et al., 2005; Zhou
et al., 2013).
Antagonists of Protein Phosphorylation
Protein phosphorylation is amajor cellular regulatorymechanism
that is often used in host-immunity-related signal transduction
cascades such as the MAPK and NF-kB pathways. AlthoughCethe ‘‘conventional’’ way of regulating the phosphorylation status
of cellular proteins is through kinases and phosphatases,
pathogens have evolved several additional unique mechanisms,
both reversible and irreversible, for antagonizing host-protein
phosphorylation.
One efficient mechanism for antagonizing the activation of a
host protein by phosphorylation is competitive modification of
the target residues. This mechanism was initially described in
2006 for the Yersinia type III effector YopJ. Based on similarities
between its catalytic domain and predicted secondary structure
of clan CE cysteine proteases, YopJ was believed for many
years to be a protease (Orth et al., 1999, 2000). It was known
to inhibit the host inflammatory response and promote
apoptosis of immune cells by preventing the activation of its
interacting host proteins: MAPK kinases (MAPKKs) and the
related kinase that activates the NF-kB pathway, IkB kinase b
(IKKb) (Orth et al., 1999, 2000). However, there was no solid
evidence indicating that inhibition of host inflammation was
protease mediated, and cleavage of the target host proteins,
MAPKKs or IKKb, was not observed (Mukherjee et al., 2006).
The actual activity of YopJ was finally revealed when Mukherjee
et al. (2006) developed a cell-free signaling system to recapitu-
late the inhibition of the MAPK and NF-kB pathways in vitro.
They noticed that activation of these signaling pathways dimin-
ished in the presence of YopJ, and they went on to show that
YopJ acts directly on MAPKKs and IKKb. The breakthrough in
understanding YopJ’s inhibitory mechanism was made possible
by emerging mass spectrometry techniques that can be used to
study protein PTMs (Mann and Jensen, 2003). Mass spectrom-
etry revealed that the total mass of a specific MAPKK, MAPKK6,
increased in increments of 42 atomic mass units when coex-
pressed with YopJ. Subsequent liquid chromatography followed
by tandem mass spectrometry identified these modifications as
acetylation, or the addition of an acetyl group to a protein.
Remarkably, the acetylated residues on MAPKK6 were a
conserved serine and threonine in the kinase activation loop,
which are the same residues that are phosphorylated by
the MAPKK kinase for activation of MAPKKs (Figure 1A). An
in vitro transferase reaction using acetyl-coenzyme A as a
donor showed that YopJ functions directly as an acetyltransfer-
ase that prevents kinase phosphorylation and activation by
adding a competitive acetyl group. These findings were laterll Host & Microbe 14, September 11, 2013 ª2013 Elsevier Inc. 271
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kherjee et al., 2006).
Although lysine acetylation (N-acetylation) was a well-estab-
lished regulatory mechanism, the studies on YopJ revealed a
novel mechanism of serine and threonine acetylation that is
used to directly compete with and prevent phosphorylation
and activation of a kinase. Surprisingly, although YopJ was pre-
dicted to function as a protease based on a conserved catalytic
triad and predicted secondary structure, it was found to be a
transferase. From a mechanistic standpoint, both proteases
and transferases can use a ping-pong mechanism for catalysis;
however, the former uses water as a substrate, whereas the
latter excludes water from its active site. It is worth noting that
members of the YopJ family of acetyltransferases have been
identified in many animal and plant pathogens and that their
targets are not limited to protein kinases.
The discovery of YopJ’s acetyltransferase activity was the first
of many that helped define a strategy for study and discovery of
novel PTMs: (1) finding a target protein; (2) identifying the molec-
ular change using the new and evolving fields of biochemistry
and mass spectrometry; and (3) elucidating the catalytic mech-
anism used to modify a protein. This strategy has led to many
surprising catalytic discoveries for virulence proteins and the
identification of several novel PTMs.
Almost as proof of principle, Shao and colleagues indepen-
dently discovered a unique PTM that antagonizes phosphoryla-
tion-mediated activation of kinases using a similar strategy. This
PTM, named eliminylation, involves the irreversible removal of
phosphate groups and is mediated by the OspF family of type
III effectors, including theShigellaOspF,SalmonellaSpvC,Chro-
mobacterium VirA, and Pseudomonas HopAI1 effectors (Li et al.,
2007) (Figure 1B). Using a cell-free signaling system similar to
that described by Mukherjee et al. (2006), Li et al. discovered
that OspF targets the MAPK Erk and attenuates its phosphoryla-
tion status. These results led Li et al. to hypothesize that OspF
harbors a phosphatase activity to reverse Erk phosphorylation.
Indeed, OspF could dephosphorylate threonine, but not tyrosine,
in the activation loop of MAPKs in vitro. Next, Li et al. subjected
phosphorylated Erk2 that had been treated with OspF to tandem
mass spectrometry analysis. The results revealed that in addition
to the loss of a phosphate group, the threonine residue also
underwent a dehydration reaction. Therefore, OspF functions
as a phosphothreonine lyase, rather than a phosphatase, that
carries out a b-eliminylation reaction to remove the phosphate
moiety from the phosphothreonine in the pT-X-pY motif of
phosphorylated MAPKs, resulting in an irreversibly inactive
kinase (Li et al., 2007) (Figure 1B).
Interestingly, a similar mechanism of catalysis was identified
recently in members of the bacterial LanL family of lanthionine
synthetases that share sequence homology with OspF family
members (Goto et al., 2011). This enzyme family is responsible
for biosynthesis of lantibiotics, a class of peptide antibiotics,
through a process that includes phosphorylation followed by
dehydration of phosphothreonine and phosphoserine (Willey
and van der Donk, 2007). Although eliminylation can be found
in bacteria, an interesting question is whether such activity exists
in eukaryotes as a regulatory mechanism to irreversibly
‘‘dephosphorylate’’ proteins. Notably, dehydrated (unsaturated)
serine and threonine were found in human proteins, but it272 Cell Host & Microbe 14, September 11, 2013 ª2013 Elsevier Incremains unclear whether these are enzyme-mediated PTMs
(Brennan and Barford, 2009).
NMPylation
In 1967, Stadtman and colleagues discovered the enzyme gluta-
mine synthetase-adenylyltransferase (GS-ATase) in E. coli.
GS-ATase uses ATP and Mg2+ to covalently modify GS, an
enzyme involved in nitrogen synthesis, by adding nucleotide
adenosinemonophosphate (AMP) to a tyrosine residue (Kingdon
et al., 1967). This modification, termed adenylylation, regulates
the activity and properties of GS. The following year, Stadtman
and colleagues reported that GS-ATase can also catalyze the
reverse reaction of deadenylylation and remove the AMP from
GS (Shapiro and Stadtman, 1968). These two findings revealed
a reversible PTM that uses AMP to modify protein characteris-
tics. Remarkably, they went on to discover that the ATase itself
undergoes PTM-mediated regulation by another nucleotidyl-
transferase through cycles of uridylylation and deuridylylation,
in which uridine monophosphate (UMP) is reversibly added
and removed from target residues. They showed that the uridy-
lylated form catalyzes the deadenylylation of GS (Brown et al.,
1971). Hence, nucleotidyltransferases can use various nucleo-
tides as substrates to modify and regulate protein activities.
Interestingly, in 1978, a non-regulatory use of uridylylation was
discovered for a viral RNA-dependent RNA polymerase (RdRp)
(Paul et al., 1998; Rothberg et al., 1978). However, the field of
protein activity regulation by nucleoside monophosphate
(NMP) modification remained relatively dormant for over 40
years until the discovery of the bacterial effector VopS.
VopS and the Fic Domain
The field of NMP modifications re-emerged as an important reg-
ulatory PTM following the discovery of the catalytic activity of the
Vibrio parahaemolyticus type III effector VopS in 2009. VopSwas
found to covalently modify host Rho GTPases with an AMP
molecule on a threonine residue, leading to the disruption of
Rho GTPase binding to downstream signaling machinery and
subsequent collapse of the actin cytoskeleton (Yarbrough
et al., 2009). This discovery relied on the strategy that was
used to identify PTMs mediated by YopJ and was ultimately
confirmed by mass spectrometry analysis of the VopS-modified
target proteins. The region within VopS that mediated the cata-
lytic activity was the ‘‘filamentation induced by cyclic AMP’’
(Fic) domain, and the name AMPylation was coined for this
PTM activity (Yarbrough et al., 2009).
Fic domains are found in a variety of bacterial species, and the
role of AMPylation in signaling has accelerated since the
discovery of VopS (Woolery et al., 2010). Dixon and colleagues
reported that IbpA, which is a toxin secreted from the bacteria
Histophilus somni and contains two Fic domains, can AMPylate
Rho GTPases to induce cytotoxicity in mammalian cells (Worby
et al., 2009). However, unlike VopS, the IbpA Fic domain
AMPylated a tyrosine residue rather than a threonine residue
(Worby et al., 2009). Notably, Dixon and colleagues also demon-
strated that IbpA-mediated AMPylation could be reversed with a
promiscuous phosphodiesterase from snake venom (Worby
et al., 2009), further supporting Stadtman’s previous observa-
tions on the reversibility of protein AMPylation (Shapiro and
Stadtman, 1968) and UMPylation (uridylylation) (Brown et al.,
1971)..
Figure 2. Legionella Uses AMPylation and
Phosphocholination to Regulate the Rab1
GTPase
Rab1 is sequestered in the cytoplasm by a
GDI. Upon infection, Rab1 is recruited to the
LCV membrane followed by activation by the
Legionella GEF DrrA. It is then modified by
either AMPylation or phosphocholination via the
bacterial effectors DrrA or AnkX, respectively. The
modified form of Rab1 cannot interact with host
GEFs and GAPs. The PTMs on activated GTP-
bound Rab1 can be reversed by deAMPylation or
dephosphocholination by the effectors SidD or
Lem3, respectively. The GTP-bound Rab1 can
then be inactivated by the Legionella GAP LepB.
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eukaryotes, including humans (Kinch et al., 2009; Worby et al.,
2009). This finding supports the hypothesis that the addition
of an NMP or NMPylation, and specifically Fic-mediated
NMPylation, is a universal PTM that is used for regulating protein
activity. More recently, Rahman et al. (2012) demonstrated that
the Drosophila Fic protein is required for neurotransmission in
fly eyes and that the deletion of this protein causes blindness.
The wild-type form, but not a catalytically inactive mutant, of
Drosophila Fic rescued the defects in fly vision (Rahman et al.,
2012).
The Nucleotidyltransferase DrrA
An exquisite example of the use of AMPylation as a reversible
regulatory PTM began with the study of the Legionella type IV
secretion system effector DrrA (SidM) (Figure 2) (Sherwood
and Roy, 2013). In 2010, Mu¨ller et al. (2010) determined the
crystal structure of DrrA, which was known to play a major role
in recruiting the small host GTPase Rab1 to the Legionella-
containing vacuole (LCV), a specialized bacteria-generated
compartment. They observed that in addition to the known
guanine nucleotide exchange factor (GEF) domain and the phos-
phatidylinositol-4-phosphate binding domain, the N-terminal
region of DrrA was structurally similar to nucleotidyltransferases
and shared the same catalytic motif as the one found in
GS-ATase (Mu¨ller et al., 2010). They went on to show that like
GS-ATase, the DrrA nucleotidyltransferase domain mediated
AMPylation of Rab1 on a tyrosine residue (Mu¨ller et al., 2010),
implicating this domain in virulent activities involving the PTM
of a host protein, similar to the Fic domain. However, subsequent
studies revealed that AMPylation of Rab1 by DrrA is only part of
this complex PTM-regulatory mechanism. Legionella uses DrrA
to recruit Rab1 to LCV membranes, where it acquires endo-
plasmic-reticulum-derived vesicles that are required for main-
taining the LCV. DrrA uses its GEF activity to activate Rab1
and maintain it on the LCV membrane. Another effector, LepB,
is a GTPase-activating protein (GAP) that can facilitate Rab1
GTP hydrolysis and thus remove Rab1 from the LCV membrane
(Ingmundson et al., 2007). However, there is a 4 hr time lapse
between DrrA-mediated activation of Rab1 and its subsequent
inactivation and release by LepB and host GAPs (Ingmundson
et al., 2007). This delay is the result of DrrA-mediated AMPylationCell Host & Microbe 14, Seof Rab1, which renders Rab1 inacces-
sible to LepB (Mu¨ller et al., 2010). These
observations led to the hypothesis thatthere is a deAMPylating enzyme that removes the AMP from
Rab1 to allow LepB to deactivate it after 4 hr. Indeed, within a
year, two groups identified SidD, a deAMPylating Legionella
effector that deAMPylates Rab1 (Neunuebel et al., 2011; Tan
and Luo, 2011). Legionella achieves this complex reversible
regulatory mechanism to modulate a host-membrane trafficking
pathway by using temporal regulation of effector translocation
into the host cell (Neunuebel et al., 2011) (Figure 2). These
discoveries underlined the regulatory and reversible role of
AMPylation as a PTM.
Regulation and Substrate Specificity for Fic Domains
Interestingly, several subsequent studies demonstrated that, like
nucleotidyltransferases, Fic domains can use various substrates
to catalyze different PTMs (Figure 2). The first non-AMPylating
Fic domain to be described was the Legionella type IV effector
AnkX. In 2011, Roy and colleagues used mass spectrometry to
study the AMPylation of Rab1 by DrrA. Surprisingly, they found
that Rab1 was also modified with another PTM and that this
modification was dependent on the Legionella type IV secretion
system but independent of DrrA (Mukherjee et al., 2011). Mass
spectrometry analysis identified the modification as phospho-
cholination, in which a phosphocholine group is added to the
serine residue directly preceding the tyrosine that is AMPylated
by DrrA. This modification is mediated by the Fic domain of
AnkX using CDP-choline as a substrate (Mukherjee et al.,
2011). As shown for DrrA, the PTM mediated by the AnkX Fic
domain was reversible. Two groups identified the Legionella
effector Lem3 (lpg0609) as a dephosphocholinase that can
remove the AnkX-mediated phosphocholine from Rab proteins
(Figure 2) (Goody et al., 2012; Tan et al., 2011). Interestingly,
AMPylation and phosphocholination of Rab1 seem to be
mutually exclusive (Goody et al., 2012).
Fic domains, like kinases, modify various residues (namely
serine, threonine, and tyrosine). Moreover, Fic-domain-
containing proteins are not strictly AMPylators, but rather phos-
photransferases with different substrate specificities. Crystal
structures of several Fic domains and their substrate-bound
states revealed that Fic domains cleave diphosphate-contain-
ing substrates and use a resulting phosphoryl-containing
moiety to modify an accepting hydroxyl group. Dehio and col-
leagues suggested that most Fic domains are controlled by aptember 11, 2013 ª2013 Elsevier Inc. 273
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the ATP-binding site (Engel et al., 2012). This inhibition can
occur in either an intramolecular or an intermolecular manner,
and mutations in the conserved motif found in the inhibitory
helix result in a considerable increase in AMPylation activity
of the enzymes (Engel et al., 2012). Cherfils and colleagues
demonstrated that the diphosphate-containing substrates are
specifically recognized by variable regions that are found
outside of the Fic catalytic motif, at both ends of the active
site (Campanacci et al., 2013). Interestingly, based on these
observations, Cherfils and colleagues recently proposed that
several structural elements in the Fic domain can determine
the nature of the physiological substrates targeted by the
enzyme. Furthermore, based on this model, they proposed
that Fic domains that were previously suggested to have low
AMPylation activity levels due to the presence of an inhibitory
a helix may actually have a physiological substrate other than
ATP (Campanacci et al., 2013). Recently, a number of molecu-
lar tools have been developed for studying this PTM, including
antibodies specific for modified residues, characteristic ions
and fragmentation patterns of AMPylated peptides, and nucle-
otide analogs (Grammel et al., 2011; Hao et al., 2011; Lewallen
et al., 2012; Li et al., 2011).
Using NMPylation to Antagonize Host-Protein Signaling
AvrAC, another Fic-domain-containing type III effector from the
phytopathogenic bacterium Xhanthomonas campestris, was
recently shown to modify its substrates with UMP (Feng et al.,
2012). AvrAC was shown to inhibit the plant immune response
by UMPylating at least two receptor-like cytoplasmic kinases,
BIK1 and RIPK, of the flowering plant Arabidopsis (Feng et al.,
2012). Remarkably, the UMPylation sites were the conserved
serine and threonine residues in the kinase activation loop that
must be phosphorylated for kinase activation. Therefore, both
AvrAC and YopJ act as antagonists and use similar mechanisms
to competitively inhibit protein kinase activation. Whereas YopJ
competes with serine and threonine phosphorylation by modi-
fying the residues with an acetyl group, AvrAC accomplishes
this inhibition by modifying these residues with UMP. This
example of phosphorylation-competitive modification further
supports the hypothesis that similar PTM strategies can also
be used in eukaryotes as a regulatory mechanism for fine-tuning
kinase activities (Figure 1C).
Ubiquitylation
The history of signaling mediated by small-protein modifications
goes back decades, long before our understanding of how
proteins were degraded in a cell, and their significance is
intertwined with the discovery of protein and membrane meta-
bolism. The initial biochemical mechanism proposed for protein
degradation was perplexing, because cells were known to
contain enzymes that efficiently hydrolyzed proteins, but these
enzymes were separated from cytoplasmic proteins by a mem-
brane (Turk and Turk, 2009). Many theories were proposed for
how these enzymes might access their substrates, including
the idea that this ‘‘suicide bag’’ of membrane-bound enzymes
could rupture, release proteases, and degrade intracellular
proteins. However, this compartment, the lysosome, is
extremely acidic, with a pH that is optimal for activities of the
enzymes contained within it. Release of these enzymes into274 Cell Host & Microbe 14, September 11, 2013 ª2013 Elsevier Incthe cytoplasm exposes them to a neutral pH, resulting in irre-
versible inactivation of the majority of the lysosomal proteases
(Turk and Turk, 2009).
The solution to the question of how cytoplasmic proteins were
metabolized camewith the discovery of the 26S proteasome and
ubiquitin-mediated degradation of proteins, a discovery for
which Hershko, Ciechanover, and Rose received the Nobel prize
in chemistry in 2004 (Goldberg, 2005). This very large enzyme
complex efficiently degrades cytosolic proteins, as well as
nuclear and membranal proteins. Additional discoveries were
made on the mechanisms that regulate protein degradation,
including a process involving the ATP-dependent modification
of proteins with the small-protein ubiquitin that directs the spe-
cific and efficient degradation of proteins by the proteasome.
Seminal findings included the deciphering of the E1-E2-E3
enzyme cascades that are required for modifying a target protein
with ubiquitin. As discussed below, thesemechanisms provide a
plethora of targets that can be hijacked, mimicked, and manipu-
lated by pathogens.
While further discoveries were being made on the regulation
and biochemical mechanism of the proteasome, another
pathway called autophagy emerged as a mechanism for the
turnover of larger cytoplasmic complexes (Choi et al., 2013).
This degradative pathway uses membranes to engulf compo-
nents of the cytoplasm into autophagic vesicles and recycle
their contents. The process involves fusion of autophagosomes
with aforementioned ‘‘suicide bag’’ for the degradation of auto-
phagosome components, resulting in the production of metab-
olites that can be reused by the cell. This pathway utilizes
cellular machinery that mediates the movement and fusion of
membranes, and these autophagic vacuoles are tagged with a
protein that is modified using a set of enzymes similar to the
E1-E2-E3 enzymes used for ubiquitylation. The autophagic
pathway is an ideal target for pathogens because of the need
to manipulate membranes during infection, as was exemplified
above with the intricate manipulation of vesicle proteins by
Legionella.
Modifying a protein with ubiquitin can result in a variety of
outcomes other than degradation. These include activation of
signaling proteins, regulation of protein-protein interactions,
and relocalization of proteins within a cell (Jiang and Chen,
2012). Herein, we focus on the degradation of ubiquitylated
proteins. This process involves an enzymatic cascade wherein
the first enzyme, E1 (ubiquitin-activating enzyme), is charged in
an ATP-dependent manner with ubiquitin. E1 then transfers
ubiquitin to an E2 (ubiquitin-conjugating enzyme), which can
either transfer the ubiquitin to an E3 (ubiquitin-protein ligase)
or be coordinated to transfer the ubiquitin directly to a target
protein by an E3. All of the E3s contain binding sites for an
E2 and the target protein(s) that are to be ubiquitylated. This
recognition site on the target protein that is destined to be
polyubiquitylated and degraded may consist of a protein
sequence that in some cases must be modified by a PTM to
be recognized (Pickart, 2001). All of these systems require tight
regulation so that a cell can properly signal and maintain
homeostasis. We discuss how the field of protein ubiquitylation,
and in particular E3-ubiquitin ligases, advanced due to the
discoveries made by elucidating the function of virulence
factors produced by pathogens..
Figure 3. Different Mechanisms and Substrates Used by
E3 Ubiquitin Ligase Families
(A) The HECT and IpaH families of E3 ligases accept ubiquitin (Ub) from an E2
and then transfer it to a lysine residue on the substrate protein.
(B) The RING E3 ligases do not accept ubiquitin from the E2, but rather
facilitate the direct transfer of ubiquitin from the E2 to a lysine residue on the
substrate.
(C) The viral K3/K5 and the eukaryotic MARCH family of E3 ligases are
membranal proteins that mediate the ubiquitylation of nonlysine residues on
substrates, such as cysteine, serine, and threonine. They can also target
membranal proteins by mediating noncanonical Lys63 and Lys11 linkages in
polyubiquitin chains, as opposed to the canonical Lys48 linkages that are
usually mediated by HECT and RING E3s.
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In 1995, Howley and colleagues made an important discovery
through their studies on human papillomavirus and one of its
oncogenic proteins, E6 (Huibregtse et al., 1995). These investi-
gators discovered that a complex of E6 together with the cellular
protein E6-AP (E6-associated protein), an E3 ubiquitin ligase,
recognized the tumor suppressor p53 and targeted it for degra-
dation by ubiquitin-mediated proteolysis. Analysis of the E6-AP
sequence revealed a number of cellular proteins that contain a
domain homologous to the C terminus of E6-AP, termed the
HECT (homologous to E6-AP carboxy-terminus) domain. E3
ubiquitin ligases containing HECT were shown to share theCeability to accept ubiquitin from an E2 in the form of a thioester
and directly transfer it to the target substrate. This discovery
thus defined the class of HECT E3 ubiquitin ligases (Rotin and
Kumar, 2009). Bacterial pathogens, such as Salmonella and
E. coli, also use effector proteins containing HECT E3s to pro-
mote infection (Lin et al., 2011; Zhang et al., 2006) (Figure 3A).
Proteins containing a RING (really interesting new gene)
domain represent a second type of E3 ubiquitin-protein ligases
(Figure 3B). These E3s act as scaffolds and coordinate the
transfer of ubiquitin from the E2 to the substrate. Because their
discovery is attributed to studies involving eukaryotic signaling
rather than pathogens, we refer the readers to an in depth E3
review (Deshaies and Joazeiro, 2009). Interestingly, pathogens
mimic this type of E3 to manipulate pathways in the host cell
(Spallek et al., 2009). For example, the XopL effector from the
plant pathogen Xanthomonas campestris pv. vesicatoria con-
tains a novel fold that mimics a scaffolding E3-ubiquitin ligase
and is implicated in disrupting plant cell host defense (Singer
et al., 2013).
Pathogen-Encoded Unique E3 Ligases
Studies by Parsot and colleagues on bacterial type III effectors
from Shigella flexineri revealed a third type of E3s that are
encoded exclusively by bacterial pathogens called IpaH (Rohde
et al., 2007). Structural analysis showed that IpaH proteins are
distinct from the HECT and RING E3s, supporting the theory
that these molecules evolved by a convergent mechanism,
possibly through a ‘‘thioesterase’’ ancestor (Singer et al., 2013;
Zhu et al., 2008). These bacterial effectors contain a leucine-
rich repeat (LRR) domain and a unique ubiquitin-protein ligase
domain that transfers ubiquitin, using a catalytic cysteine
residue, directly to its target substrate. The LRR is proposed to
provide substrate specificity for the target proteins that will be
tagged with polyubiquitin and to autoinhibit the E3 domain in
the absence of substrate (Ashida et al., 2010; Boname and
Lehner, 2011; Chou et al., 2012; Singer et al., 2013; Wang
et al., 2013). IpaH E3s have essentially highjacked the entire
ubiquitin/proteasome signaling machinery to direct the destruc-
tion of host proteins, enabling the pathogen to control the innate
immune response. Because this system is so successful, it is
used by a large number of bacterial proteins from both patho-
gens and symbionts (Figure 3A).
Finally, a forth type of ubiquitin-protein ligase was discovered
through studies on viral proteins called K3 and K5 (or MIR-1 and
MIR-2, respectively) from Kaposi’s sarcoma-associated herpes
virus. This lineage has been extensively reviewed by Boname
and Lehner (2011). In brief, these E3s resemble the RING E3
domains structurally, but have unique functional and structural
attributes that separate them from classic RING domain E3s.
The K3 ubiquitin ligases are membrane-bound enzymes that
target cell-surface receptors for destruction. Analysis of these
E3s resulted in a number of discoveries about protein ubiquity-
lation. An initial surprise that emerged from the study of K3 viral
ubiquitin ligases was that the enzymes could use nonconven-
tional amino acids, including cysteine, serine, and threonine
residues, to monoubiquitylate target proteins with the help of
a specific E2, UbcH5 (Cadwell and Coscoy, 2005; Wang
et al., 2007). Next, it was discovered that this K3 E3 could use
another E2, Ubc13, to add polyubiquitin chains to the monoubi-
quitylated target proteins. This E2 mediates the addition ofll Host & Microbe 14, September 11, 2013 ª2013 Elsevier Inc. 275
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ical lysine 48 linkages, and it is correlated with internalization
and lysosomal degradation of cell-surface receptors (Duncan
et al., 2006). Another surprising discovery was made during
further analysis of K5-mediated ubiquitylation showing that
several cell-surface receptors were targeted for destruction
via mixed chain linkages (Lys11 and Lys63) (Boname et al.,
2010). These observations revealed multiple mechanisms that
can be used to modify proteins with ubiquitin chains. Using bio-
informatics, the viral E3s where found to be similar to a group of
host proteins, subsequently called the membrane-associated
RING-CH family of E3 ligases (MARCH), that are predicted to
play a role in the turnover of cell-surface receptors (Lehner
et al., 2005) (Figure 3C).
Antagonists of Ubiquitin Elongation
As observed with phosphorylation, ubiquitylation is also a target
of pathogens, and a family of bacterial proteins called Cif-like
effectors eloquently exemplifies a manipulation that antago-
nizes this PTM (Cui et al., 2010). These proteins contain a
papain-like catalytic domain that is used to facilitate a deamida-
tion reaction, whereby a glutamine side chain is converted to a
glutamate side chain (Figure 1D). One of these effectors, CHBP
from Burkholderia pseudomallei, was shown to deamidate a
specific glutamine residue within ubiquitin and an ubiquitin-
like protein NEDD8 that is similarly conjugated to target pro-
teins. This 1 Dalton (Da) change in molecular mass results in a
ubiquitin molecule that can no longer be used in ubiquitin elon-
gation reactions, and NEDD8 that can no longer modify the
functions of its substrate proteins. This PTM causes a dramatic
change in host signaling and has thus far been shown to be
irreversible.
Conclusions and Future Directions
The study of the functional mechanisms of pathogenic enzymes
leads to a better understanding of virulence strategies, as well as
to discoveries of new cellular enzymatic activities and regulatory
mechanisms. In this review, we have presented examples of how
the study of host-pathogen interactions and PTMs that aremedi-
ated by pathogens provided valuable insights into eukaryotic cell
biology. Pathogens use PTMs, both directly and indirectly, to
manipulate the host cell and regulate host-protein activities, as
well as the activities of their own proteins. Notably, although
pathogens use various PTMs and different mechanisms, there
are common host processes and pathways that are targeted
and manipulated. These processes are mainly those required
for immunity and signal transduction (such as MAPK and
NF-kB pathways), entry of the pathogen into the host cell (the
cytoskeleton), and maintenance of a replicative niche (vesicle
trafficking). A significant point not discussed in detail is the use
of the host PTM machinery to directly regulate the function of
bacterial proteins within a host. For example, pathogenic pro-
teins can be ubiquitylated to control their stability or subcellular
localization. Some proteins have also been reported to undergo
modification with a lipid moiety to ensure their membrane local-
ization (Hicks and Gala´n, 2013; Ribet and Cossart, 2010).
It is interesting to look back and see how technological
advancements led to seminal discoveries of novel PTMs.
Following the use of radioactivity and antibodies in the early
years of PTM studies, we have recently entered the era of276 Cell Host & Microbe 14, September 11, 2013 ª2013 Elsevier Incmass spectrometry. The ability to accurately identify minor
changes (sometime only a 1 Da change) in a protein’s molecular
weight presented a huge stepping stone for discoveries of PTMs.
Based on the recently identified PTMs, it is apparent that a
strategy for studying virulence factors has emerged. This
strategy follows three central steps: finding a target protein,
using mass spectrometry techniques to identify how the target
is modified by the enzyme of interest, and finally, following
appropriate biochemical strategies to elucidate and validate
the mechanism.
Discoveries in the field of pathogen-mediated PTMs now allow
us to exploit the unique nature of these enzymes and use them as
tools to control and fine-tune cellular processes. This concept
was recently demonstrated by Lim and colleagues, who used
bacterial type III effectors with phosphothreonine lyase (OspF)
and phosphatase (YopH) activities to rewire and fine-tune kinase
signaling pathways in T cells (Wei et al., 2012). Research on
pathogen-mediated PTM is progressing and evolving rapidly
as new PTMs and new targets are discovered. We will
undoubtedly witness the discovery of more unique PTMs in the
next few years that will shed light on new regulatory mechanisms
in eukaryotic cells.
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